{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:07:24Z","timestamp":1792796844460,"version":"4.5.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Although neoadjuvant immunochemotherapy (nICT) has revolutionized the management of locally advanced esophageal squamous cell carcinoma (ESCC), the inability to accurately predict pathological complete response (pCR) remains a major barrier to treatment personalization. We aimed to develop and validate an interpretable machine learning (ML) model using pretreatment multimodal features to predict pCR prior to nICT initiation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this retrospective study, 114 ESCC patients receiving nICT were randomly allocated into training (n=81) and validation (n=33) cohorts (7:3 ratio). Predictors of pCR were identified from pretreatment clinical variables, endoscopic ultrasonography, and hematological biomarkers via least absolute shrinkage and selection operator (LASSO) regression. Eight machine learning algorithms were implemented to construct prediction models. Model performance was assessed by area under the receiver operating characteristic curve (AUC), sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). Shapley Additive Explanations (SHAP) provided feature importance and model interpretability.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Following feature selection, 17 variables were incorporated into model construction. The Random Forest (RF) model demonstrated perfect discrimination in the training cohort (AUC = 1.000, sensitivity = 1.000, specificity = 1.000, PPV = 1.000, NPV = 1.000), while maintaining robust predictive ability in the independent validation cohort (AUC = 0.913, sensitivity = 0.733, specificity = 0.889, PPV = 0.846, NPV = 0.800). Decision curve analysis (DCA) confirmed favorable clinical utility. SHAP analysis identified alcohol consumption, circumferential involvement \u226550%, elevated neutrophil-to-lymphocyte ratio (NLR), C-reactive protein (CRP), and alanine aminotransferase (ALT) as the key contributors to pCR prediction.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>We established a clinically applicable, interpretable ML model that accurately predicts pCR to nICT in ESCC by integrating multimodal pretreatment data. This tool may optimize patient selection for nICT and advance precision therapy paradigms.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1660897","type":"journal-article","created":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T05:36:37Z","timestamp":1758000997000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["An interpretable machine learning model using multimodal pretreatment features predicts pathological complete response to neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Xueping","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wencheng","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kewei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songhe","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjie","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e004291","DOI":"10.1136\/jitc-2021-004291","article-title":"Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma","volume":"10","author":"Liu","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2022.106680","article-title":"Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE)","volume":"103","author":"Yan","year":"2022","journal-title":"Int J Surg"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2023.12.030","article-title":"Neoadjuvant chemotherapy combined with immunotherapy versus neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma","volume":"168","author":"Yu","year":"2024","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30953","article-title":"Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience","volume":"123","author":"Blum","year":"2017","journal-title":"Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-023-14809-1","article-title":"Long-term survival and recurrence patterns in locally advanced esophageal squamous cell carcinoma patients with pathologic complete response after neoadjuvant chemotherapy followed by surgery","volume":"31","author":"Wu","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1599526","article-title":"The prognostic power of major pathological response in esophageal squamous cell carcinoma patients undergoing neoadjuvant chemoimmunotherapy: a multi-center cohort study","volume":"16","author":"Xie","year":"2025","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz116","article-title":"ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1\/PD-L1 expression and tumour mutational burden: a systematic review-based approach","volume":"30","author":"Luchini","year":"2019","journal-title":"Ann Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.4253\/wjge.v14.i4.205","article-title":"Role of endoscopic ultrasound in esophageal cancer","volume":"14","author":"Radlinski","year":"2022","journal-title":"World J Gastrointest Endosc"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/eus.0000000000000008","article-title":"EUS-derived maximum tumor thickness and tumor shrinkage rate as independent prognostic factors in locally advanced esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy","volume":"12","author":"Chen","year":"2023","journal-title":"Endosc Ultrasound"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1606181","article-title":"Predicting the future - big data, machine learning, and clinical medicine","volume":"375","author":"Obermeyer","year":"2016","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1814259","article-title":"Machine learning in medicine","volume":"380","author":"Rajkomar","year":"2019","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.14508","article-title":"Optimal preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma","volume":"1482","author":"Leng","year":"2020","journal-title":"Ann N Y Acad Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03064-w","article-title":"Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO\/NCCES01 trial","volume":"30","author":"Qin","year":"2024","journal-title":"Nat Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy334","article-title":"PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers","volume":"29","author":"Sabari","year":"2018","journal-title":"Ann Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e005830","DOI":"10.1136\/jitc-2022-005830","article-title":"Neoadjuvant sintilimab and chemotherapy in patients with potentially resectable esophageal squamous cell carcinoma (KEEP-G 03): an open-label, single-arm, phase 2 trial","volume":"11","author":"Chen","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1056\/NEJMc1808251","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"379","author":"Forde","year":"2018","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01962-5","article-title":"Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial","volume":"28","author":"Chaft","year":"2022","journal-title":"Nat Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma","volume":"386","author":"Doki","year":"2022","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.02.007","article-title":"Toripalimab plus chemotherapy in treatment-naive, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial","volume":"40","author":"Wang","year":"2022","journal-title":"Cancer Cell"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.7314\/apjcp.2013.14.9.4965","article-title":"Alcohol consumption and risk of cancer: a systematic literature review","volume":"14","author":"de Menezes","year":"2013","journal-title":"Asian Pac J Cancer Prev"},{"key":"B23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40164-025-00617-8","article-title":"Alcohol accelerates the development of esophageal squamous cell carcinoma through elevated Gram-negative bacteria in peripheral circulation","volume":"14","author":"Zhang","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25885","article-title":"Alcohol drinking and esophageal squamous cell carcinoma with focus on light-drinkers and never-smokers: a systematic review and meta-analysis","volume":"129","author":"Islami","year":"2011","journal-title":"Int J Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00068-024-02732-3","article-title":"Alcohol drinking leads to sex-dependent differentiation of T cells","volume":"51","author":"Sturm","year":"2025","journal-title":"Eur J Trauma Emerg Surg"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202003404","article-title":"Aldehyde dehydrogenase 2 mediates alcohol-induced colorectal cancer immune escape through stabilizing PD-L1 expression","volume":"8","author":"Zhang","year":"2021","journal-title":"Adv Sci (Weinh)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00464-020-07368-z","article-title":"Lesion size and circumferential range identified as independent risk factors for esophageal stricture after endoscopic submucosal dissection","volume":"34","author":"Chen","year":"2020","journal-title":"Surg Endosc"},{"key":"B28","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3892\/ol.2022.13644","article-title":"Neutrophil-to-lymphocyte ratio after neoadjuvant chemotherapy as an independent prognostic factor in patients with esophageal squamous cell carcinoma","volume":"25","author":"Yamada","year":"2023","journal-title":"Oncol Lett"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-08765-3","article-title":"Correlation between immunoinflammatory measures and periostin expression in esophageal squamous cell carcinoma: A single-center, retrospective cohort study","volume":"28","author":"Ishibashi","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s13304-023-01693-3","article-title":"Nomogram based on pretreatment hepatic and renal function indicators for survival prediction of locally advanced esophageal squamous cell carcinoma with treatment of neoadjuvant chemoradiotherapy plus surgery","volume":"76","author":"Lin","year":"2024","journal-title":"Updates Surg"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/wrr.12442","article-title":"Systemic depletion of macrophages in the subacute phase of wound healing reduces hypertrophic scar formation","volume":"24","author":"Zhu","year":"2016","journal-title":"Wound Repair Regener"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1660897\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T05:36:37Z","timestamp":1758000997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1660897\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,16]]},"references-count":31,"alternative-id":["10.3389\/fimmu.2025.1660897"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1660897","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,16]]},"article-number":"1660897"}}